Microbot Medical Inc. 8K

Microbot Medical filed its Q2 2026 Form 10-Q and reported over 100% quarter-over-quarter revenue and customer growth for its LIBERTY Endovascular Robotic System, alongside major commercial expansion, new partnerships, and international regulatory clearance in Israel.

On August 11, 2026, Microbot Medical Inc. announced via Form 8-K that it has filed its Form 10-Q for the quarter ended June 30, 2026, reporting that revenue and customer count more than doubled versus the first quarter of 2026, driven by the transition of its LIBERTY Endovascular Robotic System from Limited Market Release to Full Market Release, adoption by new health systems in multiple U.S. states, increased procedure volumes and hospital sites, and high customer satisfaction leading to repeat orders. The company highlighted operational and commercial milestones including expanded U.S. sales territories, an agreement with Lovell Government Services to access over 2,000 federal healthcare facilities, an agreement with Sanmina to establish a second manufacturing site for capacity expansion and cost reduction, and receipt of marketing clearance in Israel as the first jurisdiction outside the U.S. for LIBERTY, while noting that it is implementing cost reduction initiatives to substantially lower cost of revenue going forward and preparing for European commercialization subject to obtaining a CE Mark.

Filing Facts

CIK

883975

Ticker

-

Form

8K

Source Type

sec

Accession

0001493152-26-037031

Alert Tier

7